title: New drugs should be judged on "willingness to pay" basis, says leading economist.
authors.forename: Jacqui
authors.initials: J
authors.lastname: Wise
mesh_terms: D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000188:drug therapy; D006301:Health Services Needs and Demand / Q000191:economics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics; D055553:Prescription Drugs / Q000191:economics*
chemical_list: D007004:Hypoglycemic Agents; D055553:Prescription Drugs